EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Superior asthma control with the FP/salmeterol combination product BID versus oral montelukast QD as first-line therapy



Superior asthma control with the FP/salmeterol combination product BID versus oral montelukast QD as first-line therapy



Journal of Allergy & Clinical Immunology 107(2): S98, February




(PDF emailed within 1 workday: $29.90)

Accession: 035796461

Download citation: RISBibTeXText



Related references

First-line therapy with fluticasone propionate/salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone. Journal of Allergy & Clinical Immunology 109(1 Supplement): S252, January, 2002

Reduction in asthma-related exacerbations and exacerbation-related costs during initial maintenance therapy with fluticasone propionate/salmeterol combination product versus montelukast or fluticasone propionate alone. Journal of Allergy & Clinical Immunology 111(2 Abstract Supplement): S143, February, 2003

Fluticasone propionate/salmeterol diskus combination product provides superior asthma control compared with fluticasone propionate and salmeterol alone in patients previously receiving PRN short-acting beta2-agonists alone. Journal of Allergy & Clinical Immunology 109(1 Supplement): S245, January, 2002

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. Journal of Allergy and Clinical Immunology 104(3 Pt 1): 547-553, 1999

A fixed combination of fluticasone and salmeterol permits better control of asthma than a beclomethasone dipropionate and montelukast combination. European Annals of Allergy and Clinical Immunology 35(9): 356-362, 2004

Cost-effectiveness analysis of fluticasone propionate/salmeterol combination versus montelukast in the treatment of adults with asthma. Journal of Allergy & Clinical Immunology 109(1 Supplement): S185, January, 2002

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids. Chest 119(4): 1021-1026, 2001

A comparison of using fluticasone propionate/salmeterol combination versus adding montelukast in asthma patients experiencing symptoms on inhaled corticosteroids. Chest 118(4 Suppl ): 85S, October, 2000

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. Journal of Allergy and Clinical Immunology 106(6): 1088-1095, 2000

Comparative efficacy of combination of fluticasone and salmeterol; fluticasone, salmeterol and montelukast; fluticasone, salmeterol, and levocetirizine in moderate persistent asthma: A study of 120 patients. Chest 132(4): 512a-1, 2007

Body mass index and response to asthma therapy: fluticasone propionate/salmeterol versus montelukast. Journal of Asthma 47(1): 76-82, 2010

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respiratory Medicine 97(3): 234-241, 2003

Administrative claims analysis of asthma-related health care utilization for patients who received inhaled corticosteroids with either montelukast or salmeterol as combination therapy. Journal of Managed Care Pharmacy 12(4): 310-321, 2006

Asthma control with fluticasone propionate/salmeterol 100/50mug Diskus versus montelukast in patients previously receiving short-acting beta2-agonists. Journal of Allergy & Clinical Immunology 113(2 Supplement): S117, February, 2004

The combination of salmeterol and fluticasone improves asthma-related health outcomes at lower cost compared to the combination of inhaled corticosteroids and montelukast. Journal of Allergy & Clinical Immunology 107(2): S101, February, 2001